- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00763919
Customized Medication Adherence Enhancement for Treating Adults With Bipolar Disorder
Customized Adherence Enhancement in Bipolar Disorder (CAE in BD)
Study Overview
Status
Conditions
Detailed Description
Bipolar disorder (BPD) is a chronic disorder characterized by manic and depressive episodes that disrupt healthy, functional lives. Despite recent advances in medication treatments, many BPD patients do not take their medications. Medication nonadherence is associated with multiple risks, such as relapse, rehospitalization, lengthier hospital stays, and, in some cases, increased risk of suicide. Some studies have shown that treatment adherence in BPD can be improved, particularly through psychological education, development of self-management strategies or behaviors, and ongoing relapse prevention.
This study will examine the effectiveness of medication adherence treatment modules specialized to deal with specific reasons for nonadherence. Participants, all of whom have a history of medication nonadherence, will undergo structured interviews and complete self-report questionnaires to determine individual reasons for nonadherence. Based on their individual profiles, participants will be assigned to one or more of the following intervention modules:
- Psychoeducation: This module uses education about BPD and related treatment to address patient issues such as opposition to preventive efforts, denial of the need for or effectiveness of medication, negative attitudes toward drugs in general, lack of information about mood stabilizers, and stigma or embarrassment related to BPD treatment.
- Substance abuse: This module targets substance abuse problems that interfere with medication adherence.
- Communication with providers: This module addresses fear of medication side effects by improving communication with health care providers.
- Medication routines management: This module addresses difficulties establishing a medication routine and outside opposition to medications by developing strategies for consistent medication adherence routines.
Each module will involve four 60-minute sessions conducted in a 4- to 6-week period. The study therapist will conduct each of these sessions individually with the participant, combining or coadministering modules in a single session if participants are assigned to more than one module. Depending on which module or modules participants are assigned to, they may also be contacted by phone one to three times by the therapist to complete all module materials.
This study will be conducted in two phases. In the first, an initial group of participants will undergo the module treatments and then participants and therapists will be interviewed about the effectiveness and feasibility of the interventions. This feedback will be used to refine the modules. In the second phase, a second group of participants will undergo treatment in the refined modules and provide more feedback. All participants will continue with their regular treatment while undergoing module treatments.
Participation in this study will last 4 to 6 weeks, with follow-up interviews and assessments ending 6 months after completion of the intervention. In all, there will be five assessments, completed at an initial screening visit, just before treatment, just after treatment, and 3 and 6 months after the completion of treatment. The initial assessments will last 60 to 90 minutes and involve questionnaires and a structured interview. The other four assessments will last 45 to 60 minutes. Treatment adherence, attitudes toward medications, BPD symptoms, and overall functioning will be measured at each assessment. The number of pills used in each participant's prescription bottles will also be counted as a measure of medication adherence.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Ohio
-
Cleveland, Ohio, United States, 44122
- Connections
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Clinical diagnosis of bipolar disorder (BPD) Type I or Type II, as determined by a standardized diagnostic interview, the Mini-International Neuropsychiatric Interview (MINI)
- Demonstrated history of poor medication adherence, as determined by self-report or clinician report. In this study, self-reported treatment nonadherence will be identified with the Tablet Routines Questionnaire (TRQ). Poorly adherent individuals will be defined as those who miss 30% or more of medication within either the past week or past month (those missing 30% or more within past week will be considered to be nonadherent over the past month). Clinician-assessed nonadherence will be identified via a clinician version of the TRQ to identify nonadherence of 30% or more over the past 30 days.
- BPD of at least 2 years' duration
- Treatment with medication to stabilize mood for at least 6 months
Exclusion Criteria:
- Unable/unwilling to participate in psychiatric interviews, as based on the clinical opinion of the investigator or the treating clinician
- High risk of suicide, as seen in factors such as active suicidal ideation, recent suicide attempt, or current intent or plan
- Inability to speak English
- Individuals who have participated in Project 1, Personal Adherence Evaluation of Individuals Receiving Treatment for Bipolar Disorder (PAE in BD)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Customized Adherence Enhancement (CAE)
Participants, all of whom have a history of medication nonadherence, will be assigned to one or more treatment modules based on their individual profiles. Treatment Modules: Psychoeducation module Substance abuse module Improved communication/rapport with provider module Medication routines management module |
The psychoeducation module will use psychological and medication education to address opposition to prophylaxis, denial of illness severity or therapeutic effectiveness, negative attitudes toward drugs in general, lack of information about mood stabilizers, and stigma or embarrassment over medications or in relation to the use of complementary or alternative treatments.
The substance abuse module will address problematic substance abuse, particularly as it relates to medication adherence.
The provider communication and rapport module will improve health care provider communication to address fear of side effects, concern regarding change in appearance, or side effect-related distress.
The medication routines management module will develop strategies and behaviors that help create medication adherence routines for those who have difficulties with medication routines or experience outside opposition to medications.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Treatment Adherence Within the Past Month as Measured by the Tablet Routines Questionnaire
Time Frame: baseline and 6 months
|
The minimum score is 0 and the maximum score is 100.
A higher score implies poorer treatment adherence.
|
baseline and 6 months
|
Change in Treatment Adherence Within the Past Week as Measured by the Tablet Routines Questionnaire
Time Frame: baseline and 6 months
|
The minimum score is 0 and the maximum score is 100.
A higher score implies poorer treatment adherence.
|
baseline and 6 months
|
Change in Treatment Adherence as Measured by the Morisky Scale
Time Frame: baseline and 6 months
|
The minimum score is 0 and the maximum score is 4. A higher score implies poorer treatment adherence.
|
baseline and 6 months
|
Change in Treatment Adherence Within the Past Month as Measured by the Tablet Routines Questionnaire
Time Frame: baseline and 3 months
|
The minimum score is 0 and the maximum score is 100.
A higher score implies poorer treatment adherence.
|
baseline and 3 months
|
Change in Treatment Adherence Within the Past Week as Measured by the Tablet Routines Questionnaire
Time Frame: baseline and 3 months
|
The minimum score is 0 and the maximum score is 100.
A higher score implies poorer treatment adherence.
|
baseline and 3 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Attitude as Measured by the Attitude Toward Mood Stabilizers Questionnaire (AMSQ)
Time Frame: baseline and 6 months
|
The AMSQ is a modification of the Lithium Attitudes Questionnaire.
The minimum score is 0 and the maximum score is 19.
A higher score implies a poorer attitude.
|
baseline and 6 months
|
Change in Attitude as Measured by the Rating of Medication Influences (ROMI)
Time Frame: baseline and 6 months
|
The minimum score is 0 and the maximum score is 10.
A higher score implies a poorer attitude.
|
baseline and 6 months
|
Change in Depression as Measured by the Hamilton Rating Scale for Depression (HAM-D)
Time Frame: baseline and 6 months
|
The minimum score is 0 and the maximum score is 52.
A higher score implies a worse condition.
|
baseline and 6 months
|
Change in Symptoms of Bipolar Disorder as Measured by the Young Mania Rating Scale (YMRS)
Time Frame: baseline and 6 months
|
The minimum score is 0 and the maximum score is 60.
A higher score implies a worse condition.
|
baseline and 6 months
|
Change in Symptoms of Bipolar Disorder as Measured by the Brief Psychiatric Rating Scale (BPRS)
Time Frame: baseline and 6 months
|
The minimum score is 18 and the maximum score is 126.
A higher score implies a worse condition.
|
baseline and 6 months
|
Change in Global Psychopathology as Measured by the Clinical Global Impression for Bipolar Disorder (CGI-BP)
Time Frame: baseline and 6 months
|
The minimum score is 1 and the maximum score is 7.
A higher score implies a worse condition.
|
baseline and 6 months
|
Change in Functional Status as Measured by the Global Assessment of Functioning (GAF) Scale
Time Frame: baseline and 6 months
|
The minimum score is 1 and the maximum score is 100.
A higher score implies higher functioning.
|
baseline and 6 months
|
Change in Perception of Physical Health as Measured by the 12-item Short Form Health Survey (SF-12)
Time Frame: baseline and 6 months
|
The minimum score is 1 and the maximum score is 99.
A higher score implies higher perceived physical health.
|
baseline and 6 months
|
Change in Perception of Mental Health as Measured by the 12-item Short Form Health Survey (SF-12)
Time Frame: baseline and 6 months
|
The minimum score is 1 and the maximum score is 99.
A higher score implies higher perceived mental health.
|
baseline and 6 months
|
Change in Depression as Measured by the Hamilton Rating Scale for Depression (HAM-D)
Time Frame: baseline and 3 months
|
The minimum score is 0 and the maximum score is 52.
A higher score implies a worse condition.
|
baseline and 3 months
|
Change in Symptoms of Bipolar Disorder as Measured by the Young Mania Rating Scale (YMRS)
Time Frame: baseline and 3 months
|
The minimum score is 0 and the maximum score is 60.
A higher score implies a worse condition.
|
baseline and 3 months
|
Change in Symptoms of Bipolar Disorder as Measured by the Brief Psychiatric Rating Scale (BPRS)
Time Frame: baseline and 3 months
|
The minimum score is 18 and the maximum score is 126.
A higher score implies a worse condition.
|
baseline and 3 months
|
Change in Global Psychopathology as Measured by the Clinical Global Impression for Bipolar Disorder (CGI-BP)
Time Frame: baseline and 3 months
|
The minimum score is 1 and the maximum score is 7.
A higher score implies a worse condition.
|
baseline and 3 months
|
Change in Functional Status as Measured by the Global Assessment of Functioning (GAF) Scale
Time Frame: baseline and 3 months
|
The minimum score is 1 and the maximum score is 100.
A higher score implies higher functioning.
|
baseline and 3 months
|
Change in Attitude as Measured by the Attitude Toward Mood Stabilizers Questionnaire (AMSQ)
Time Frame: baseline and 3 months
|
The AMSQ is a modification of the Lithium Attitudes Questionnaire.
The minimum score is 0 and the maximum score is 19.
A higher score implies a poorer attitude.
|
baseline and 3 months
|
Change in Attitude as Measured by the Rating of Medication Influences (ROMI)
Time Frame: baseline and 3 months
|
The minimum score is 0 and the maximum score is 10.
A higher score implies a poorer attitude.
|
baseline and 3 months
|
Change in Perception of Physical Health as Measured by the 12-item Short Form Health Survey (SF-12)
Time Frame: baseline and 3 months
|
The minimum score is 1 and the maximum score is 99.
A higher score implies higher perceived physical health.
|
baseline and 3 months
|
Change in Perception of Mental Health as Measured by the 12-item Short Form Health Survey (SF-12)
Time Frame: baseline and 3 months
|
The minimum score is 1 and the maximum score is 99.
A higher score implies higher perceived physical health.
|
baseline and 3 months
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- R34MH078967-02 (U.S. NIH Grant/Contract)
- R34MH078967 (U.S. NIH Grant/Contract)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Bipolar Disorder
-
ProgenaBiomeRecruitingBipolar Disorder | Bipolar I Disorder | Bipolar II Disorder | Bipolar Type I Disorder | Bipolar Disorder Mild | Bipolar Disorder Moderate | Bipolar Disorder SevereUnited States
-
Rush University Medical CenterThe Ryan Licht Sang Bipolar FoundationCompletedBipolar Disorder | Bipolar Depression | Bipolar I Disorder | Bipolar Disorder I | Bipolar Affective DisorderUnited States
-
University of PittsburghNational Alliance for Research on Schizophrenia and DepressionCompletedBipolar I Disorder | Bipolar II Disorder | Bipolar Disorder NOSUnited States
-
Region StockholmKarolinska InstitutetRecruitingBipolar Disorder | Bipolar Depression | Bipolar I Disorder | Bipolar II Disorder | Bipolar Affective Disorder; Remission in | Bipolar Affective Disorder, Currently Depressed, ModerateSweden
-
Hospital de Clinicas de Porto AlegreFederal University of Rio Grande do Sul; Hospital Moinhos de VentoActive, not recruitingBipolar Disorder | Bipolar Depression | Major Depressive Disorder | Bipolar I Disorder | Affective Disorder | Bipolar II DisorderBrazil
-
Medical University of South CarolinaMilken InstituteCompletedBipolar Disorder | Bipolar I Disorder | Bipolar II DisorderUnited States
-
Joshua RosenblatRecruitingBipolar Disorder | Bipolar Depression | Bipolar I Disorder | Bipolar II DisorderCanada
-
Mayo ClinicCompletedMajor Depressive Disorder, Bipolar I and Bipolar IIUnited States
-
Joshua RosenblatRecruitingBipolar Disorder | Bipolar Depression | Bipolar I Disorder | Bipolar II DisorderCanada
-
Myriad Genetic Laboratories, Inc.University of MinnesotaCompletedMajor Depressive Disorder, Bipolar I and Bipolar IIUnited States
Clinical Trials on Psychoeducation module
-
University Hospitals Cleveland Medical CenterCase Western Reserve UniversityCompletedBipolar DisorderUnited States
-
Nencki Institute of Experimental Biology of the...Institute of Psychology, Polish Academy of Sciences; SWPS University of Social...Recruiting
-
Nencki Institute of Experimental Biology of the...University of Social Sciences and Humanities, Warsaw; National Science Centre... and other collaboratorsActive, not recruiting
-
Haukeland University HospitalNot yet recruitingIBS - Irritable Bowel Syndrome
-
University of NimesNot yet recruitingWellbeing | Emotional Distress | Psychosocial Problem | Functional Impairment | User ExperienceFrance
-
Istituto Auxologico ItalianoRecruiting
-
Universiti Sains MalaysiaUniversiti Teknologi Mara; Ministry of Health, MalaysiaRecruitingPrimary Open Angle Glaucoma | Primary Angle Closure GlaucomaMalaysia
-
The University of Texas Health Science Center,...TerminatedBipolar Disorder Family MembersUnited States
-
Total Child Health, Inc.University of California, Los AngelesWithdrawn
-
IRCCS Centro San Giovanni di Dio FatebenefratelliAlzheimer's Association; University of BergamoRecruiting